BillionToOne

BillionToOne is a precision diagnostics company based in Menlo Park, California, founded in 2016. With a team of around 300 employees, the company aims to enhance molecular diagnostics by making them more accurate, efficient, and accessible. Their proprietary technology, Quantitative Counting Templates (QCTs™), allows for the detection and measurement of disease-related DNA fragments at single base-pair resolution, significantly improving prenatal screening and liquid biopsy applications. The company's flagship product, UNITY™ Screen, is a noninvasive prenatal test that analyzes fetal cell-free DNA from a maternal blood sample, assessing risks for various genetic conditions and chromosomal aneuploidies. BillionToOne also offers UNITY Complete®, which combines multiple screening options into one test. In oncology, they provide liquid biopsy tests like Northstar Select™ and Northstar Response™ to help determine cancer treatment and monitor therapy effectiveness. Additionally, they have developed a COVID-19 test, showcasing their technology's versatility. BillionToOne serves pregnant patients, oncology patients, and clinical research organizations, and has experienced significant growth and recognition in the diagnostics field.